PDE5 inhibitors: considerations for preference and long-term adherence
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PDE5 inhibitors: considerations for preference and long-term adherence
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Volume 67, Issue 8, Pages 768-780
Publisher
Wiley
Online
2013-07-22
DOI
10.1111/ijcp.12074
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Randomized Open‐Label Trial with a Crossover Comparison of Sexual Self‐Confidence and Other Treatment Outcomes Following Tadalafil Once a Day Vs. Tadalafil or Sildenafil On‐Demand in Men with Erectile Dysfunction
- (2012) Eusebio Rubio‐Aurioles et al. Journal of Sexual Medicine
- Couples' Reasons for Adherence to, or Discontinuation of, PDE Type 5 Inhibitors for Men with Erectile Dysfunction at 12 to 24‐Month Follow‐Up after a 6‐Month Free Trial
- (2012) Helen M. Conaglen et al. Journal of Sexual Medicine
- Selectivity of Avanafil, a PDE5 Inhibitor for the Treatment of Erectile Dysfunction: Implications for Clinical Safety and Improved Tolerability
- (2012) Run Wang et al. Journal of Sexual Medicine
- A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Safety and Efficacy of Avanafil in Subjects with Erectile Dysfunction
- (2012) Irwin Goldstein et al. Journal of Sexual Medicine
- Avanafil, a Potent and Highly Selective Phosphodiesterase-5 Inhibitor for Erectile Dysfunction
- (2012) Jun Kotera et al. JOURNAL OF UROLOGY
- Safety of Prescribing PDE-5 Inhibitors via e-Medicine vs Traditional Medicine
- (2012) Mark A. Munger et al. MAYO CLINIC PROCEEDINGS
- Vardenafil Orodispersible Tablet
- (2011) Mark Sanford DRUGS
- A Therapeutic Confirmatory Study to Assess the Safety and Efficacy of Zydena® (Udenafil) for the Treatment of Erectile Dysfunction in Male Patients with Diabetes Mellitus
- (2011) Du Geon Moon et al. Journal of Sexual Medicine
- Time to Onset of Action of Vardenafil: A Retrospective Analysis of the Pivotal Trials for the Orodispersible and Film‐Coated Tablet Formulations
- (2011) Frans M.J. Debruyne et al. Journal of Sexual Medicine
- A Randomized, Double‐Blind, Placebo‐Controlled, Parallel Study to Assess the Efficacy and Safety of Once‐A‐Day Tadalafil in Men with Erectile Dysfunction Who Are Naïve to PDE5 Inhibitors
- (2011) Francesco Montorsi et al. Journal of Sexual Medicine
- Are Phosphodiesterase Type 5 Inhibitors Associated with Vision‐Threatening Adverse Events? A Critical Analysis and Review of the Literature
- (2011) Faris Azzouni et al. Journal of Sexual Medicine
- Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: Opening windows to enhanced sexual function and overall health
- (2011) Richard Sadovsky et al. Journal of the American Academy of Nurse Practitioners
- A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition
- (2010) Ferdinando Fusco et al. BJU INTERNATIONAL
- Pharmacokinetics of a New Orodispersible Tablet Formulation of Vardenafil
- (2010) Roland Heinig et al. CLINICAL DRUG INVESTIGATION
- Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: A single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers
- (2010) Jinah Jung et al. CLINICAL THERAPEUTICS
- Guidelines on Male Sexual Dysfunction: Erectile Dysfunction and Premature Ejaculation
- (2010) Konstantinos Hatzimouratidis et al. EUROPEAN UROLOGY
- The future is today: emerging drugs for the treatment of erectile dysfunction
- (2010) Maarten Albersen et al. EXPERT OPINION ON EMERGING DRUGS
- Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction
- (2010) Ma Limin et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction
- (2010) Philip Dorsey et al. EXPERT OPINION ON PHARMACOTHERAPY
- The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction
- (2010) M. Gittelman et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Giving Patients with Erectile Dysfunction the Opportunity to Try All Three Available Phosphodiesterase Type 5 Inhibitors Contributes to Better Long-Term Treatment Compliance
- (2010) Christina Ljunggren et al. Journal of Sexual Medicine
- Durability of Response Following Cessation of Tadalafil Taken Once Daily as Treatment for Erectile Dysfunction
- (2010) Hartmut Porst et al. Journal of Sexual Medicine
- Tadalafil and vardenafil vs sildenafil: a review of patient-preference studies
- (2009) Vincenzo Mirone et al. BJU INTERNATIONAL
- Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success
- (2009) R Shabsigh et al. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
- Phosphodiesterase-5 inhibitors oppose hyperoxic vasoconstriction and accelerate seizure development in rats exposed to hyperbaric oxygen
- (2009) Ivan T. Demchenko et al. JOURNAL OF APPLIED PHYSIOLOGY
- Effect of phosphodiesterase-5 inhibitor on hearing
- (2009) S Okuyucu et al. JOURNAL OF LARYNGOLOGY AND OTOLOGY
- Safety, Efficacy, and Pharmacokinetic Overview of Low-Dose Daily Administration of Tadalafil
- (2009) Rebecca Wrishko et al. Journal of Sexual Medicine
- Continuing Medical Education: 2009 Update on Phosphodiesterase Type 5 Inhibitor Therapy Part 2: Updates on Optimal Utilization for Sexual Concerns and Rare Toxicities in This Class (CME)
- (2009) Alan W. Shindel Journal of Sexual Medicine
- Erectile Dysfunction and Cardiovascular Disease: Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both Conditions
- (2009) Ajay Nehra MAYO CLINIC PROCEEDINGS
- EEG abnormalities during treatment with tadalafil, a phosphodiesterase type 5 inhibitor
- (2009) Esra E. Okuyucu et al. NEUROLOGICAL RESEARCH
- Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects
- (2008) Bo-Hyung Kim et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Role of Sildenafil in Neurological Disorders
- (2008) Muhammad U. Farooq et al. CLINICAL NEUROPHARMACOLOGY
- Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option
- (2008) Craig F. Donatucci et al. CURRENT MEDICAL RESEARCH AND OPINION
- Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress
- (2008) Serap Gur et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction
- (2008) M J Thurtell et al. INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
- Long-Term Safety and Efficacy of Tadalafil 5 mg Dosed Once Daily in Men with Erectile Dysfunction
- (2008) Hartmut Porst et al. Journal of Sexual Medicine
- The Efficacy and Safety of Udenafil, a New Selective Phosphodiesterase Type 5 Inhibitor, in Patients with Erectile Dysfunction
- (2008) Jae-Seung Paick et al. Journal of Sexual Medicine
- Importance of and Satisfaction with Sex Among Men and Women Worldwide: Results of the Global Better Sex Survey
- (2008) John Mulhall et al. Journal of Sexual Medicine
- Evaluation of Patient Expectations and Treatment Satisfaction after 1-Year Tadalafil Therapy for Erectile Dysfunction: The DETECT Study
- (2008) Petros Perimenis et al. Journal of Sexual Medicine
- Efficacy and Tolerability of Lodenafil Carbonate for Oral Therapy in Erectile Dysfunction: A Phase II Clinical Trial
- (2008) Sidney Glina et al. Journal of Sexual Medicine
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started